Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 7/20 | 0.50 |
| ▸ | KIT | P10721 | 6/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.50 |
| ▸ | FLT4 | P35916 | 5/20 | 0.50 |
| ▸ | FLT3 | P36888 | 5/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.48 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816982 | 0.90 | KDM4E (0.57) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL16226363 | 0.85 | KDM4E (0.53) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL16227154 | 0.84 | ELANE (0.56) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL11030544 | 0.83 | BRD4 (0.46) | KDM4EGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7639538 | 0.81 | KDM4E (0.49) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL25307258 | 0.81 | EGFR (0.42) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL228911 | 0.81 | MEN1 (0.53) | GAAALDH1A1ELANEMAPTEGFR | |
| SCHEMBL30550465 | 0.81 | EGFR (0.42) | KDM4EGAASMN1; SMN2KDRKIT | |
| SCHEMBL11260702 | 0.80 | MAOA (0.52) | SMN1; SMN2ALDH1A1MAPTMAPK1MKNK2 | |
| SCHEMBL21098689 | 0.80 | EGFR (0.41) | KDM4EGAASMN1; SMN2KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | KDM4E 4285/4885GAA 193/4885SMN1; SMN2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.